Reports Q3 revenue $119M vs. $178M last year. As of September 30, Inhibrx had cash and cash equivalents of $337.3M vs. $192.5M at June 30.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INBX:
